Liquidityhelp
lock$14.41K
Total value locked
$20.93
24h volume
Yieldhelp
trending_up0.1%
advertised APRFee yield, annualized
≈ -29.2%
adjusted · net of IL (est.)
My Position
account_balance_walletAI Verdict
Proceed with Caution
WealthVille AI evaluation verdict for this liquidity pool investment opportunity.
Use a narrow, actively monitored range and rebalance whenever price reaches either boundary; exit rather than widen the range if DRUGS liquidity deteriorates or fee volume stops justifying the inventory risk.
syncAI analysis is refreshing in the background
Performance Breakdown
| Metric | 24h / Day | 7d / Week | 30d / Month |
|---|---|---|---|
| Total APR | 0.1% | — | — |
| Fee APR | 0.1% | — | — |
| Volume | $20.93 | — | — |
| Fees Earned | $0.05 | — | — |
Data sourced from Raydium Protocol, Birdeye, and DexScreener. Updated every snapshot cycle.
Efficiency Metrics
ComputedDeterministic efficiency metrics computed from on-chain data for this liquidity pool. All values are calculated directly from pool analytics — not AI-generated.
Pool Rankings
#1 of 3 SOL-DRUGS pools
by AI Farmer Score
#14125 of 93745 on raydium-amm
by AI Farmer Score
Top 14% of all Solana pools
overall rank #20307 of 150817
How This Pool Works
Beginner FriendlyThis page provides real-time AI analytics and performance data for the SOL-DRUGS liquidity pool on Raydium AMM. Data is sourced from on-chain Solana activity, Birdeye, DexScreener, and CoinGecko.
Providing liquidity here means depositing SOL and DRUGS into a shared trading pool and receiving part of the swap fees. You can lose value relative to simply holding the tokens if their prices move apart, and withdrawing may become harder if DRUGS trading activity falls.
Pool Analysis
trending_upYield Source Breakdown
The stated APR decomposes into 0.1% from swap fees and 0.0% from rewards. 100% of yield comes from trading fees, so realized returns depend directly on continued volume rather than an emission schedule. No reward-duration estimate is available, and there is no current reward component to cushion a decline in fee generation.
shieldRisk Assessment
Seven-day impermanent-loss history and tick-in-range exposure are not available for this pool, limiting quantitative assessment of recent price divergence and range utilization. As a MEMECOIN pool, SOL-DRUGS carries sharp token-specific volatility, liquidity withdrawal, and adverse selection risk. Emission decay is less immediate here because the stated return is fee-funded, but exit timing still matters: a reduction in trading activity or deterioration in DRUGS liquidity can make closing the position more difficult and reduce fee income.
tollSOL Context
SOL is the liquid base asset in this pair and generally has deeper liquidity elsewhere on Solana than DRUGS. SOL price movements relative to DRUGS determine the pool's inventory mix and can create impermanent loss when SOL trends sharply in either direction. Stronger SOL liquidity can help execution, but it does not remove the pair-level risk from DRUGS.
tollDRUGS Context
DRUGS is the memecoin side of the pair, so its liquidity depth and price discovery are more dependent on this pool and other venue-specific markets. A rapid DRUGS repricing can shift the LP toward the declining asset while arbitrageurs capture stale pricing. Its price action is therefore the main source of idiosyncratic risk for this position.
lightbulbSimple Explanation
Providing liquidity here means depositing SOL and DRUGS into a shared trading pool and receiving part of the swap fees. You can lose value relative to simply holding the tokens if their prices move apart, and withdrawing may become harder if DRUGS trading activity falls.
Token Details
Pool Details
- Pool Address
- G8WWDEBxBa2jamKKrfRUUw9AJAb3e6KoV9RhwuMeLdGp
- Protocol
- Raydium AMM
- Chain
- solana
- Fee Tier
- —
- Pool Type
- AMM
- Token A
- SOL (So111111…)
- Token B
- DRUGS (CX9YDTED…)
- Created
- 4/22/2026
Explore More
Similar Pools — Same Protocol
APR
13%
APR
0%
APR
0%
APR
6%
By Protocol
hubAll raydium-amm poolsarrow_forwardBlockchain
dnsAll Solana poolsarrow_forwardNon-Custodial
Your funds are never held by WealthVille. All positions are on-chain.
Verified Data Sources
Raydium, Birdeye, DexScreener, CoinGecko, LlamaYield
AI-Powered Analysis
Proprietary scoring model trained on historical Solana DeFi data
⚠️ WealthVille AI analytics are for informational purposes only. APR, TVL, and AI scores are based on historical and real-time data and do not constitute financial advice. DeFi investments carry significant risk including impermanent loss and smart contract risk. Always do your own research.
Frequently Asked Questions
The current reward-only APR is 0.0%, while fee-only APR is 0.1% and fee sustainability is 100%. Because the stated yield is fee-funded, emission decay is not the present source of APR decline; weaker trading volume is.
The current reward-only APR is 0.0%, while fee-only APR is 0.1% and fee sustainability is 100%. Because the stated yield is fee-funded, emission decay is not the present source of APR decline; weaker trading volume is.
The reward component would fall away or remain absent, leaving trading fees as the source of LP income. For SOL-DRUGS, that means the remaining APR would be represented by 0.1%, with total APR then dependent on continued volume.
The reward component would fall away or remain absent, leaving trading fees as the source of LP income. For SOL-DRUGS, that means the remaining APR would be represented by 0.1%, with total APR then dependent on continued volume.
Risk is high relative to a major-asset pair because DRUGS can reprice sharply and may have thinner liquidity. This pool has $14K TVL, 0.00x volume-to-TVL turnover, and no available recent IL or range-use history to quantify the exposure.
Risk is high relative to a major-asset pair because DRUGS can reprice sharply and may have thinner liquidity. This pool has $14K TVL, 0.00x volume-to-TVL turnover, and no available recent IL or range-use history to quantify the exposure.
Consider exiting when DRUGS liquidity deteriorates, price reaches the edge of your range without a clear recovery, or fee generation no longer compensates for inventory risk. A TVL drain or sustained volume decline would also weaken the case for remaining in SOL-DRUGS.
Consider exiting when DRUGS liquidity deteriorates, price reaches the edge of your range without a clear recovery, or fee generation no longer compensates for inventory risk. A TVL drain or sustained volume decline would also weaken the case for remaining in SOL-DRUGS.
A reliable break-even period cannot be calculated because recent impermanent-loss history and tick-in-range data are unavailable. With fee-only APR of 0.1%, recovery depends on future trading fees and whether SOL and DRUGS return toward their entry price relationship.
A reliable break-even period cannot be calculated because recent impermanent-loss history and tick-in-range data are unavailable. With fee-only APR of 0.1%, recovery depends on future trading fees and whether SOL and DRUGS return toward their entry price relationship.
